FDAsafety guidance72% confidence
Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to AbbVie.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Schizophrenia
- Sub-indication
- General
Related signal: B2227 vs. Vraylar: Pharmacokinetics Study in Schizophrenia Launched